Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study - 31/12/17
on behalf of the
ADJUVANT investigators†
Summary |
Background |
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB–IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II–IIIA (N1–N2) NSCLC.
Methods |
We did a randomised, open-label, phase 3 trial at 27 centres in China. We enrolled patients aged 18–75 years with completely resected (R0), stage II–IIIA (N1–N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC. Patients were stratified by N stage and EGFR mutation status and randomised (1:1) by Pocock and Simon minimisation with a random element to either gefitinib (250 mg once daily) for 24 months or intravenous vinorelbine (25 mg/m2 on days 1 and 8) plus intravenous cisplatin (75 mg/m2 on day 1) every 3 weeks for four cycles. The primary endpoint was disease-free survival in the intention-to-treat population, which comprised all randomised patients; the safety population included all randomised patients who received at least one dose of study medication. Enrolment to the study is closed but survival follow-up is ongoing. The study is registered with ClinicalTrials.gov, number NCT01405079.
Findings |
Between Sept 19, 2011, and April 24, 2014, 483 patients were screened and 222 patients were randomised, 111 to gefitinib and 111 to vinorelbine plus cisplatin. Median follow-up was 36·5 months (IQR 23·8–44·8). Median disease-free survival was significantly longer with gefitinib (28·7 months [95% CI 24·9–32·5]) than with vinorelbine plus cisplatin (18·0 months [13·6–22·3]; hazard ratio [HR] 0·60, 95% CI 0·42–0·87; p=0·0054). In the safety population, the most commonly reported grade 3 or worse adverse events in the gefitinib group (n=106) were raised alanine aminotransferase and asparate aminotransferase (two [2%] patients with each event vs none with vinorelbine plus cisplatin). In the vinorelbine plus cisplatin group (n=87), the most frequently reported grade 3 or worse adverse events were neutropenia (30 [34%] patients vs none with gefitinib), leucopenia (14 [16%] vs none), and vomiting (eight [9%] vs none). Serious adverse events were reported for seven (7%) patients who received gefitinib and 20 (23%) patients who received vinorelbine plus cisplatin. No interstitial lung disease was noted with gefitinib. No deaths were treatment related.
Interpretation |
Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant NSCLC. Based on the superior disease-free survival, reduced toxicity, and improved quality of life, adjuvant gefitinib could be a potential treatment option compared with adjuvant chemotherapy in these patients. However, the duration of benefit with gefitinib after 24 months might be limited and overall survival data are not yet mature.
Funding |
Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine; National Health and Family Planning Commission of People’s Republic of China; Guangzhou Science and Technology Bureau; AstraZeneca China.
Le texte complet de cet article est disponible en PDF.Plan
Vol 19 - N° 1
P. 139-148 - janvier 2018 Retour au numéro
Article précédent
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
- Marco Colleoni, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O’Reilly, Vincenzo Di Lauro, Andrea Gombos, Thomas Ruhstaller, Harold Burstein, Karin Ribi, Jürg Bernhard, Giuseppe Viale, Rudolf Maibach, Manuela Rabaglio-Poretti, Richard D Gelber, Alan S Coates, Angelo Di Leo, Meredith M Regan, Aron Goldhirsch, SOLE Investigators, An Vandebroek, Martine Berliere, Carine Mitine, Peter Vuylsteke, Marleen Borms, Randal D’Hondt, Philippe Glorieux, Jeroen Mebis, Didier Verhoeven, Michael Coibion, Frederic Forget, Lionel Duck, Didier Verhoeven, Wim Wyendaele, Annelore Barbeaux, Jean-Paul Salmon, Patrick Berteloot, Joanna Vermeij, Vincent Richard, Saverio Cinieri, Lorenzo Gianni, Mario Clerico, Graziella Pinotti, Antonio Bernardo, Leo Biganzoli, Alessandra Gennari, Claudio Graiff, Dino Amadori, Rodolfo Passalacqua, John Forbes, Prudence Francis, Serene Foo, Frances Boyle, Andrew Redfern, Andre van der Westhuizen, Craig Lewis, Sharad Sharma, Philip Beale, Ian Byard, Stephen Begbie, Frank Sardelic, Ehtesham Abdi, David Clark, Aaron Chindewere, Stephen Della-Fiorentina, Ray Asghari, Mohammed Islam, Lee Na Teo, Shane White, Linda Gilbert, Katherine Gardner, Catarina Uhlmann, Daniel Rauch, Meinrad Mannhart, Katharina Buser, Konstantin Dedes, Andreas Mueller, Christoph Rageth, Stephanie Von Orelli, Hans Joerg Senn, Olivia Pagani, Augusto Pedrazzini, Christoph Rochlitz, Alexandre Bodmer, Sandro Anchisi, Khalil Zaman, Roger von Moos, Daniel Betticher, Elena Kralidas, Razven Popescu, Mathias Fehr, Per Nyman, Anja Jungquist, Chaido Chamalidou, Theodoros Foukakis, Charlotta Dabrosin, Antonis Valachis, Istvan Lang, Zsuzsanna Kahan, Javier Retamales, Ulloa Roberto Torres, Marcela Fritis, Sebastian Sole, Soledad Torres, Jaime Letzkus, Paula Escobar, Ines Vigneaux, Jorge Arancibia, Juana Bernardita Cardemil, Patricio Huidobro, Henry Gomez, Julie Wetter, Daniel Vorobiof, Gary McMichael, Justus Apffelstaedt, Igor Vorotnikov, Joel Schwartz, Thomas Openshaw, Herve Bonnefoi, Jean-Philippe Jacquin, Natalie Bonichon-Lamichhane, Simona Borstner, Ashwini Budrukkar, Marianne Ewertz, Oscar Zambrano Quispe, Peter Michael Vestlev, Hella Danø, Ditte Nielsen, Erik Jakobsen, Inger Hoejris, Jurij Antonovic Bogovic, Britta Bjerregaard Jensen, Knud Aage Møller, Eric Lars Stenbygaard, Ravi Sharma, Carolyn Bedi, Maria Bews-Hair, Glyn Neades, Mike McKirdy, Matthew Barber, Abdulla Alhasso, Diana Ritchie, Judith Fraser, Lucy Scott, Frances Yuille, Alison Lannigan, Dermot Murphy, Mike Shere, Christian Jackisch, Oliver Tomé, Susanne Steer, Doris Augustin, Kristina Lübbe, Christian Jackisch, Heike Köcker-Korus, Jörg-Uwe Deuker, Andrea Stefek, Marianne Just, Uwe Rhein, Christina Bechtner, Dirk-Toralf Baerens, Iris Schrader, Eva-Maria Grischke, Ralf Lorenz, Wolfgang Dietz, Jörg Thomalla, Jörg Schilling, Andreas Rempen, Heiko Graf, Gabriele Doering, Steffi Busch, Georg Heinrich, Hans Tesch, Christoph Uleer, Petra Krabisch, Siegfried Rösel, Christian Kurbacher, Horst Ostertag, Klaus-M Josten, Carsten Hielscher, Isolde Gröll, Ute Marie Mattner, Anita Prechtl, Tilmann Lantzsch, Eva Ciruelos, Isabel Garau, Meritxell Bellet, Miguel Angel Climent, Rafael López, Juan Antonio Virizuela, Begoña Bermejo, Noelia Martinez Janez, Kepa Amillano, Raúl Márquez, Joan Dorca, Maria Jose Godes, Santiago Gonzalez, Shinji Ohno, Tomoyuki Aruga, Daisuke Yotsumoto, Yutaka Yamamoto, Tomohiko Aihara, Takashi Morimoto, Hiroko Bando, Norikazu Masuda, Masakazu Toi, Kenjiro Aogi, Nobuaki Sato, Morihito Okada, Masato Takahashi, Eriko Tokunaga, Hiroji Iwata, Takashi Fujita, Michael Fridrik, Gunda Pristauz, Claudia Hackl, Christian Singer, Victor Wette, Michael Gnant, Josef Thaler, Richard Greil, Burghard Abendstein, Dietmar Heck, Diether Manfreda, Paul Sevelda, Irene Thiel, Frank Tuttlies, Herbert Stöger, Walter Neunteufel, John Crown, John Kennedy, Arnold Hill, John McCaffrey, Conleth Murphy, Linda Coate, Maccon Keane, Michael Martin, Miriam O’Connor, Karen Duffy, Barbara Ruepp, Martine Piccart, Dimitrios Zardavas
- Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
- D Ross Camidge, Eudocia Q Lee, Nancy U Lin, Kim Margolin, Manmeet S Ahluwalia, Martin Bendszus, Susan M Chang, Janet Dancey, Elisabeth G E de Vries, Gordon J Harris, F Stephen Hodi, Andrew B Lassman, David R Macdonald, David M Peereboom, David Schiff, Ricardo Soffietti, Martin J van den Bent, Jeffrey S Wefel, Patrick Y Wen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?